Reagan Jarvis, our CEO, is presenting Anocca – ‘Showcasing Individualised Neoantigen Discovery Platform’ – and will be talking about understanding HLA-restricted neoantigen target complexity with cell-based assays, validating neoantigen targets with T-cell Receptor reagents derived by rapid multiplex discovery and considering TCR potency and safety trade-off for HLA-restricted neoantigens.
Reach out to us if you would like to meet.
